European Equities Traded in the US as American Depositary Receipts Fall Sharply in Tuesday Trading

MT Newswires Live09-10

European equities traded in the US as American depositary receipts were moving sharply lower late Tuesday morning, falling 1.21% to 1,404.91 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by biopharmaceutical company DBV Technologies (DBVT) and biotech firm BioNTech (BNTX), which rose 2.6% and 2.3%, respectively. They were followed by semiconductor company Sequans Communications (SQNS) and furniture maker Natuzzi (NTZ), which were down 1.5% and 1.4%, respectively.

The decliners from continental Europe were led by telecommunications company VEON (VEON) and medical device maker EDAP TMS (EDAP), which retreated 6.9% and 3.5%, respectively. Biopharmaceutical firm Grifols (GRFS) lost 3.3% and financial services company Banco Santander (SAN) was down 2.8%.

From the UK and Ireland, the gainers were led by biopharmaceutical companies Akari Therapeutics (AKTX) and TC Biopharm (TCBP), which advanced 8.5% and 3.9%, respectively. They were followed by biopharmaceutical companies Bicycle Therapeutics (BCYC) and Mereo BioPharma Group (MREO), which rose 3.6% and 2.3%, respectively.

The decliners from the UK and Ireland were led by financial services companies Barclays (BCS) and Lloyds Banking Group (LYG), which fell 3% and 2.8%, respectively. Biopharmceutical company NuCana (NCNA) was down 2.6% and financial services company HSBC (HSBC) lost 2.3%.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment